Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €255.25 EUR
Change Today +0.65 / 0.26%
Volume 613.0
IDP On Other Exchanges
As of 1:36 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

biogen inc (IDP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - €447.80
52 Week Low
10/16/14 - €228.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOGEN INC (IDP)

biogen inc (IDP) Details

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS – SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer’s disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS – DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company has a strategic partnership with BioMotiv, LLC. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

7,550 Employees
Last Reported Date: 02/4/15
Founded in 1978

biogen inc (IDP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $698.4K
Chief Strategy Officer and Senior Vice Presid...
Total Annual Compensation: $2.3M
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $625.6K
Compensation as of Fiscal Year 2014.

biogen inc (IDP) Key Developments

BioMotiv, LLC Enters into Strategic Partnership with Biogen

BioMotiv, LLC announced that it has entered into a strategic partnership with Biogen. This discovery collaboration will leverage the strengths of both organizations to identify pioneering neuroscience discoveries and advance them into medicines. Biogen has committed to invest $15 million in BioMotiv over five years, providing Biogen with exclusive rights relating to neuroscience programs sourced and developed by BioMotiv.

Biogen Enters License Pact for Mitsubishi Tanabe Pharma's Phase 2 Molecule for Autoimmune Diseases

Biogen reported an agreement to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications, from Mitsubishi Tanabe Pharma Corp. (MTPC). MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor. Biogen noted that it is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn's disease, and other autoimmune indications. The compound has completed a successful Phase 2 clinical trial in MS and Biogen is evaluating a rapid development program in this indication. The company will also investigate indications in inflammatory bowel disease. Biogen will initiate a clinical trial in ulcerative colitis and may advance an existing program in Crohn's disease to Phase 3. In a release, the company noted that under terms of the agreement, it will receive worldwide rights to MT-1303, excluding Asia. Biogen will be responsible for global commercialization and also cover development costs outside of Asian territories. MTPC will receive an upfront payment of $60 million from Biogen and may receive up to $484 million in additional milestone payments for multiple indications and territories. MTPC has the right to participate in Biogen's global clinical trials and has an option to co-promote non-MS indications in the U.S.

Biogen Inc. Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015 11:00 AM

Biogen Inc. Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015 11:00 AM. Venue: Boston, Massachusetts, United States. Speakers: Kiran Reddy, Senior Director, Corporate Strategy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDP:GR €255.25 EUR +0.65

IDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.38 USD +0.62
Astellas Pharma Inc ¥1,544 JPY -31.00
Celgene Corp $116.44 USD +3.58
Shire PLC 4,513 GBp +13.00
Thermo Fisher Scientific Inc $124.49 USD +2.39
View Industry Companies

Industry Analysis


Industry Average

Valuation IDP Industry Range
Price/Earnings 19.6x
Price/Sales 6.6x
Price/Book 5.4x
Price/Cash Flow 17.5x
TEV/Sales 6.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at